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Nonalcoholic fatty liver disease (NAFLD) is the hepatic
manifestation of obesity and metabolic syndrome
and contributes to increased risk of cardiovascular
disease and liver-related morbidity and mortality.
Indeed, obese patients with metabolic syndrome
generate greater amounts of thrombin, an indica-
tion of coagulation cascade activation. However, the
role of the coagulation cascade in Western diet–
induced NAFLD has not been investigated. Using an
established mouse model of Western diet–induced
NAFLD, we tested whether the thrombin receptor
protease-activated receptor 1 (PAR-1) and hemato-
poietic cell–derived tissue factor (TF) contribute to
hepatic steatosis. In association with hepatic steatosis,
plasma thrombin-antithrombin levels and hepatic fi-
brin deposition increased significantly in C57Bl/6J mice
fed a Western diet for 3 months. PAR-1 deficiency re-
duced hepatic inflammation, particularly monocyte
chemoattractant protein-1 expression and macrophage
accumulation. In addition, PAR-1 deficiency was associ-
ated with reduced steatosis in mice fed a Western diet,
including reduced liver triglyceride accumulation and
CD36 expression. Similar to PAR-1 deficiency, hemato-
poietic cell TF deficiency was associated with reduced
inflammation and reduced steatosis in livers of low-
density lipoprotein receptor–deficient mice fed a West-
ern diet. Moreover, hematopoietic cell TF deficiency re-
duced hepatic fibrin deposition. These studies indicate
that PAR-1 and hematopoietic cell TF are required
2278for liver inflammation and steatosis in mice fed a
Western diet. (Am J Pathol 2011, 179:2278–2289; DOI:
10.1016/j.ajpath.2011.07.015)
Obesity is a risk factor for the development of metabo-
lic syndrome (MetS).1 Nonalcoholic fatty liver disease
(NAFLD), the hepatic manifestation of MetS, is estimated
to affect at least 25% of the Western population.2 NAFLD
manifests as an excess accumulation of triglycerides in
hepatocytes (ie, steatosis) but can transition to the more
severe nonalcoholic steatohepatitis, which, if left un-
checked, may lead to fibrosis and cirrhosis.3,4 There is
increasing evidence to suggest that hepatic steatosis is
not just a benign precursor of nonalcoholic steatohepa-
titis but rather a central component of multiple dis-
eases.5,6 Indeed, disruption of key hepatic functions, in-
cluding glucose and lipid homeostasis7,8 and altered
synthesis of proteins involved in hemostasis9,10 and in-
flammation,11 may contribute not only to NAFLD but also
to an increased risk of cardiovascular disease11,12 and
diabetes.5
Many studies examining the development of steatosis
focus on changes in lipid metabolism. In patients with
NAFLD, increased hepatic free fatty acid uptake, de novo
synthesis of free fatty acids in the liver, and the conver-
sion of free fatty acids to triglycerides that are stored in
hepatocytes8,13 yield a liver histologic profile typified by
macrovesicular and microvesicular steatosis.14,15 Al-
though hepatocytes synthesize and store lipids in
NAFLD, several studies indicate that proinflammatory cy-
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monocyte chemoattractant protein-1 (MCP-1), are re-
sponsible for mediating changes in gene expression that
contribute to the development of steatosis.16–20 For ex-
ample, expression of the fatty acid transporter CD36 in
livers of obese mice is MCP-1 dependent.21 These stud-
ies indicate that inflammatory mediators are among
the necessary stimuli for lipid accumulation in hepato-
cytes.
One potential modifier of the hepatic inflammatory re-
sponse in NAFLD is the coagulation cascade. The coag-
ulation cascade is initiated by tissue factor (TF), resulting
in generation of the serine protease thrombin. Thrombin
cleaves circulating fibrinogen to fibrin monomers that are
cross-linked into insoluble fibrin clots.22 In addition to its
classic role in hemostasis, thrombin also triggers intra-
cellular signaling by activating protease-activated recep-
tor 1 (PAR-1), a tethered ligand G protein–coupled
receptor.23 Obesity and MetS are associated with coag-
ulation cascade activation in patients, as indicated by
increased thrombin generation.24–26 Moreover, weight
loss is associated with decreased TF expression and a
reduction in thrombin generation.27,28 An imbalance in
hepatic synthesis of several coagulation factors causing
a procoagulant state has been observed in patients with
NAFLD.9,10,29–31 Increased coagulation cascade activa-
tion in patients with NAFLD is often viewed as potentially
increasing the risk of cardiovascular events. In contrast,
the possibility that the coagulation cascade acts as a
critical determinant of diet-induced hepatic steatosis has
not been investigated in detail.
One potential mechanism whereby thrombin could
contribute to fatty liver disease is by increasing the pro-
duction of inflammatory mediators responsible for steato-
sis. PAR-1 contributes to TNF and MCP-1 expression in
mice fed a methionine/choline–deficient (MCD) diet.32
The MCD diet elicits hepatic changes consistent with
nonalcoholic steatohepatitis, but it is not an appropriate
model of NAFLD associated with MetS.33 The mechanism
of hepatic steatosis triggered by an MCD diet is vastly
different from that triggered by a Western diet. For exam-
ple, MCP-1 contributes to steatosis in mice fed a Western
diet18,19 but does not contribute to steatosis in mice fed
an MCD diet.34 In agreement with these studies, we
showed previously that PAR-1 deficiency did not affect
steatosis in mice fed an MCD diet, despite marked inhi-
bition of MCP-1 expression.32 The role of the coagulation
cascade in regulating inflammation and steatosis in
Western diet–induced NAFLD is not known.
We tested the hypothesis that coagulation cascade
activation is increased in mice fed a Western diet and
contributes to the development of steatosis. We evalu-
ated the possibility that thrombin signaling through PAR-1
contributes to liver inflammation and steatosis in mice fed
a Western diet using PAR-1–deficient mice. Moreover,
using bone marrow transplantation, we tested the hypoth-
esis that TF expressed by hematopoietic cells contributes
to hepatic coagulation, inflammation, and steatosis in
mice fed a Western diet.Materials and Methods
Mice, Bone Marrow Transplantation, and
Experimental Diets
Wild-type C57Bl/6J mice purchased from The Jackson
Laboratory (Bar Harbor, ME) were fed a control diet
[AIN-93M (10% kcal from fat); Dyets Inc., Bethlehem,
PA] or a Western diet [Diet #100244 (40% kcal from
milk fat); Dyets Inc.] ad libitum for 12 weeks. PAR-1/
and PAR-1/ mice35 backcrossed eight generations
onto a C57Bl/6J background were maintained by ho-
mozygous breeding. Age-matched PAR-1/ and
PAR-1/ mice were fed a control diet or a Western
diet ad libitum for 12 weeks. Average food intake was
measured weekly for each cage of mice, and mice
were weighed weekly.
Bone marrow transplantation was performed as de-
scribed previously.36 Male 8-week-old low-density lipo-
protein receptor–deficient (LDLr/) mice were irradi-
ated with 11 Gy (two doses of 550 rad each, 4 hours
apart) using a Cs137 irradiator (JL Shepherd, San Fer-
nando, CA). Irradiated mice were repopulated with bone
marrow cells isolated from heterozygous control mice
(mTF/hTF mice; n  10 recipients) or “low TF” mice
(mTF/hTF mice; n  9 recipients) via retro-orbital
injection of 2  106 cells. Low-TF mice express human TF
at a level approximately 1% of wild-type mice, and this
low level of expression rescues the embryonic lethality.37
Four weeks after injection of donor cells, mice were fed a
Western diet [Teklad TD.88137 (40% kcal from milk fat);
Harlan Laboratories, Madison, WI] ad libitum for 12
weeks. This diet has a formulation identical to Diet
#100244 from Dyets Inc. The bone marrow of recipient
mice was genotyped to verify successful repopulation of
donor cells as described previously.37 All the studies
were approved by the Animal Care and Use Committee
of the different institutions and complied with National
Institutes of Health guidelines.
Sample Collection
Under isoflurane anesthesia, blood was collected from
the caudal vena cava into sodium citrate (final concen-
tration, 0.38%) for the collection of plasma and into an
empty syringe for the collection of serum. Citrated whole
blood was subjected to centrifugation at 4000  g for 10
minutes, plasma was collected, and the buffy coat was
collected into TRI Reagent (Molecular Research Center
Inc., Cincinnati, OH). Sections of liver from the left lateral
lobe were fixed in 10% neutral-buffered formalin for 48
hours and embedded in paraffin. The right medial lobe
was affixed to a cork using optimal cutting temperature
compound (Fisher Scientific, Pittsburgh, PA) and im-
mersed for approximately 3 minutes in liquid nitrogen–
chilled isopentane. The remaining liver was snap frozen
in liquid nitrogen.
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and Determination of Hepatic Lipid Levels
Paraffin-embedded livers were sectioned at 5 m and were
stained with H&E. The severity of liver steatosis was evalu-
ated by a pathologist (O.T.) in a blinded manner. Oil Red O
staining was performed as previously described.38 Plasma
thrombin-antithrombin (TAT) levels were determined using
a commercially available enzyme-linked immunosorbent
assay kit (Siemens Healthcare Diagnostics, Deerfield, IL).
Lipids were extracted from 100 mg of snap-frozen liver as
described,32 and hepatic and serum triglyceride and cho-
lesterol levels were determined using commercially avail-
able reagents (Pointe Scientific Inc., Canton, MI; and Wako,
Richmond, VA).
RNA Isolation, cDNA Synthesis, and Real-Time PCR
Total RNA was isolated from the buffy coat of blood
samples (ie, white blood cells) and from approximately
100 mg of snap-frozen liver using TRI Reagent (Molecular
Research Center Inc.) per the manufacturer’s protocol.
One microgram of RNA was used for the synthesis of
cDNA using a high-capacity cDNA reverse transcription
kit (Applied Biosystems, Foster City, CA) and a C1000
thermal cycler (Bio-Rad Laboratories, Hercules, CA).
Levels of stearoyl-CoA desaturase 1 (SCD1), CD36, ste-
rol regulatory element binding protein-1c (SREBP-1c),
peroxisome proliferator-activated receptor- (PPAR),
fatty acid synthase (FAS), TNF, MCP-1, TF mRNA, and
18S rRNA were determined using either TaqMan gene
expression assays (Applied Biosystems) or TaqMan
PrimeTime quantitative PCR assays (IDT, Coralville, IA),
iTaq  ROX supermix (Bio-Rad Laboratories), and a
StepOnePlus thermal cycler (Applied Biosystems). Mouse
CD36 (NM_007643) primer sequences were 5=-GCGACAT-
GATTAATGGCACAG-3= (forward primer), 5=-GATCCGAA-
CACAGCGTAGATAG-3= (reverse primer), and 5=-/56-FAM/
CAACAAAAG/ZEN/GTGGAAAGGAGGCTGC/3IABkFQ/-3=
(probe). Mouse SCD1 (NM_009127) primer sequences
were 5=-CTGACCTGAAAGCCGAGAAG-3= (forward primer),
5=-AGAAGGTGCTAACGAACAGG-3= (reverse primer), and
5=-/56-FAM/TGTTTACAA/ZEN/AAGTCTCGCCCCAGCA/
3IABkFQ/-3= (probe). Mouse SREBP-1c (NM_011480) primer
sequences were 5=-CCATCGACTACATCCGCTTC-3= (for-
ward primer), 5=-GCCCTCCATAGACACATCTG-3= (reverse
primer), and 5=-/56-FAM/TCTCCTGCT/ZEN/TGAGCTTC-
TGGTTGC/3IABkFQ/-3= (probe). Mouse FAS (NM_007988)
primer sequences were 5=-CCCCTCTGTTAATTGGCTCC--
3= (forward primer), 5=-TTGTGGAAGTGCAGGTTAGG-3=
(reverse primer), and 5=-/56-FAM/CAGGCTCAG/ZEN/GGT-
GTCCCATGTT/3IABkFQ/-3= (probe). Mouse PPAR (NM_
011144) primer sequences were 5=-CATTTCCCTGTTT-
GTGGCTG-3= (forward primer), 5=-ATCTGGATGGTTGC-
TCTGC-3= (reverse primer), and 5=-/56-FAM/ATAATTTGC/
ZEN/TGTGGAGATCGGCCTGG/3IABkFQ/-3= (probe). Mouse
TF (F3) (NM_010171) primer sequences were 5=-CA-
GTTCATGGAGACGGAGAC-3= (forward primer), 5=-CAAC-
CACGTTCAGTTTTCTACC-3= (reverse primer), and 5=-/56-
FAM/AGACACAAA/ZEN/CCTCGGACAGCCAG/3IABkFQ/-3= (probe). 18S (NM_003286) primer sequences were
5=-CTGTAGCCCTGTACTTCATCG-3= (forward primer),
5=-CTACCACATATTCCTGACCATCC-3= (reverse
pr imer) , and 5 = - /56-FAM/CCTTCCTCC/ZEN/TT
TTCATTGCCTGCTCT/3IABkFQ/-3= (probe). CD36,
SCD1, FAS, SREBP-1c, PPAR, TF, and 18S primers and
probes were purchased from IDT. Mouse TNF and
MCP-1 gene expression assays were purchased from
Applied Biosystems (TNF, Assay ID Mm00443258_m1;
MCP-1, Assay ID Mm00441242_m1). The expression of
each gene was adjusted relative to 18S expression lev-
els, and the relative expression level was determined
using the comparative CT method.
Macrophage and Fibrin Staining
Frozen livers were sectioned at 8 m for staining. Mac-
rophages were identified in liver by CD68 and F4/80
staining, which was performed as previously de-
scribed.32 Immunofluorescent staining for insoluble fibrin
was performed as described previously39 using a rabbit
anti-human fibrinogen antibody (A0080; Dako, Carpinte-
ria, CA). The primary antibody was detected by the ad-
dition of goat anti-rabbit IgG conjugated to Alexa 594
(Invitrogen, Carlsbad, CA). Slides were then washed and
counterstained with DAPI (Invitrogen).
Cytokine Enzyme-Linked Immunosorbent Assays
Total protein was isolated from approximately 100 mg of
snap-frozen liver using PBS containing 0.1% Triton X-100
and Halt protease and phosphatase inhibitor cocktail
(ThermoFisher Scientific, Waltham, MA). Samples were
rotated for 30 minutes at 4°C and then were subjected to
centrifugation at 12,000  g for 15 minutes at 4°C. Protein
concentrations were determined using a DC protein as-
say (ThermoFisher Scientific). The concentrations of
TNF and MCP-1 in 225 g of protein were determined
using commercially available DuoSet enzyme-linked im-
munosorbent assays (R&D Systems, Minneapolis, MN).
Multiplex Suspension Array
The concentration of TNF and MCP-1 protein in serum
was determined using a MilliPlex mouse metabolic mag-
netic bead kit (Millipore, Billerica, MA) and a Bio-Plex 200
System (Bio-Rad Laboratories). Phycoerythrin and xMAP
bead fluorescence was detected by a dual-laser detector
(532 and 635 nm) and Bio-Plex Manager 5.0 software
(Bio-Rad Laboratories).
Western Blot Analysis
Total protein was isolated from approximately 100 mg
of snap-frozen liver using radioimmunoprecipitation
assay buffer containing Halt protease and phospha-
tase inhibitors (ThermoFisher Scientific). Protein con-
centrations were determined using a DC protein assay
(ThermoFisher Scientific). Samples were reduced by
heating to 95°C for 5 minutes in the presence of 2-mer-
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12% Bis-Tris gels; Bio-Rad Laboratories), and trans-
ferred to Immobilon polyvinylidene difluoride mem-
brane (Millipore) by semidry transfer. The membranes
were blocked for 1 hour at room temperature in 3%
bovine serum albumin in Tris-buffered saline with
Tween-20 and incubated overnight at 4°C with either
anti-CD36 (1:1000) antibody or anti-PPAR (1:1000)
antibody (BioVision, Mountain View, CA) diluted in 1%
bovine serum albumin in Tris-buffered saline with
Tween-20 or anti-SCD1 (1:1000) antibody (Cell Signal-
ing Technology Inc., Danvers, MA) diluted in 5% bo-
vine serum albumin in Tris-buffered saline with Tween-
20. Membranes were then washed with Tris-buffered saline
with Tween-20 and incubated for 1 hour with anti-rabbit
horseradish peroxidase–conjugated secondary antibody
(1:1000) (Jackson ImmunoResearch Laboratories Inc.,
West Grove, PA). Membranes were incubated with West
Pico electrochemiluminescence reagent (ThermoFisher
Scientific) before exposure to Blue Lite autoradiography film
(ISC Bioexpress, Kaysville, UT). Before the addition of anti-
bodies, membranes were stained with Ponceau S for 15
minutes and were destained with ddH2O to confirm equal
loading of protein, as previously described.40,41 Densitom-
etry was performed using Quantity One 4.6.9 software (Bio-





































Figure 1. Procoagulant response associated with Western diet–induced
steatosis in C57Bl/6J mice. Mice were fed either a control diet or a
Western diet for 12 weeks. A–D: Representative photomicrographs show-
ing H&E-stained (A and B) and fibrin-stained (red) (C and D) liver
sections from mice fed a control diet (A and C) or a Western diet (B and
D). Scale bars  20 m. E: Plasma TAT levels were determined. Data are
expressed as mean  SEM. F: The level of TF mRNA in the buffy coat
(white blood cells) was determined by real-time PCR. Data are expressed
as mean  SEM and as fold change versus mice fed a control diet.
n  6 to 10 mice per group. *P  0.05 versus mice fed the control diet.Rad Laboratories).Statistics
Statistics were performed using SigmaPlot 11.0 software
(Systat Software, Inc., San Jose, CA). Comparison of two
groups was performed using a Student’s t-test. Comparison
of three or more groups was performed using two-way anal-
ysis of variance followed by the Student-Newman-Keuls
post hoc test for multiple comparisons. Data are expressed
as mean  SEM. The criterion for statistical significance
was P  0.05.
Results
Hepatic Steatosis and Coagulation Are
Increased in C57Bl/6J Mice Fed a Western Diet
Mice fed a control diet gained 47.5%  2.5% body
weight over 12 weeks, whereas mice fed a Western
diet gained 92.1%  2.5% body weight (P  0.05).
Microvesicular and macrovesicular steatosis was evi-
dent in livers of mice fed a Western diet but not in livers
of mice fed a control diet, as indicated by histologic
features (Figure 1, A and B). To determine whether the
coagulation cascade was activated in mice fed a West-
ern diet, we measured the plasma TAT level, which is a
stable marker for thrombin generation (ie, coagulation
cascade activation). Plasma TAT levels were signifi-
cantly increased in mice fed a Western diet compared
with mice fed a control diet (Figure 1E). To determine
whether the coagulation cascade was activated in liv-
ers of mice fed a Western diet, we evaluated hepatic















































































Figure 2. Effect of PAR-1 deficiency on inflammatory cytokine induction in
mice fed a Western diet. PAR-1/ and PAR-1/ mice were fed either a
control diet or a Western diet for 12 weeks. Hepatic levels of (A) TNF mRNA
and (B) MCP-1 mRNA were determined by real-time PCR. Data are expressed
as mean  SEM and as a fold change versus PAR-1/ mice fed a control
diet. *Significantly different from mice of the same genotype fed the control
diet, P  0.05. **Significantly different from PAR-1/ mice fed the same diet,
P  0.05. Serum (C) and hepatic (D) levels of MCP-1 protein in mice fed a
Western diet were determined by Multiplex or enzyme-linked immunosor-
bent assay as stated in Materials and Methods. Data are expressed as mean 
/SEM. n  7 to 10 mice per group. Significantly different from PAR-1 mice
fed the same diet, P  0.05.
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fed a Western diet compared with mice fed a control
diet (Figure 1, C and D), indicating a local increase in
coagulation in the liver. Because previous studies sug-
gested that hematopoietic cells, such as monocytes,
could be a source of TF in obesity and MetS,42,43 we
measured TF mRNA levels in the buffy coat (white
blood cells) isolated from blood of wild-type mice fed a
control diet or a Western diet. White blood cell TF
mRNA expression was increased significantly in mice
fed a Western diet (Figure 1F).
PAR-1 Deficiency Reduces Inflammation in
Livers of Mice Fed a Western Diet
Previous studies have indicated a role for inflammation
in the development of hepatic steatosis in mice fed
a Western diet.18,19,44 – 46 One possible mechanism
whereby thrombin could contribute to inflammation is
by activating the receptor PAR-1. To evaluate the role

















Figure 3. Effect of PAR-1 deficiency on macrophage accumulation and steato
a control diet or a Western diet for 12 weeks. Representative photomicrograp
liver sections (B, E, H, and K), and Oil Red O–stained liver sections (C, F, I, and
PAR-1/ (G–I) and PAR-1/ (J–L) mice fed a Western diet. Scale bars  20 m.Western diet, we used PAR-1/ mice. Plasma TAT
levels tended to increase similarly in PAR-1/ and
PAR-1/ mice fed a Western diet, indicating that
PAR-1 deficiency does not modulate activation of the
coagulation cascade (data not shown). Expression of
hepatic TNF and MCP-1 mRNA was increased in
PAR-1/ mice fed a Western diet, and this was sig-
nificantly reduced by PAR-1 deficiency (Figure 2, A
and B). Serum and liver MCP-1 protein concentrations
were also significantly decreased in PAR-1/ mice
fed a Western diet compared with in PAR-1/ mice
fed a Western diet (Figure 2, C and D). However, serum
and liver TNF protein levels were not significantly
increased in mice fed a Western diet, and there was no
difference in TNF protein expression in PAR-1/
mice compared with PAR-1/ mice fed a Western diet
(data not shown). In addition, hepatic macrophage
accumulation increased in PAR-1/ mice fed a West-
ern diet, and this increase was largely prevented by






ers of mice fed a Western diet. PAR-1/ and PAR-1/ mice were fed either
D68 and F4/80–stained (brown) liver sections (A, D, G, and J), H&E-stained
/ /sis in liv
hs of CL) in PAR-1 (A–C) and PAR-1 (D–F) mice fed a control diet and in
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Mice Fed a Western Diet
PAR-1 deficiency did not significantly affect food intake
(data not shown) or weight gain. PAR-1/ mice fed a
control diet gained 16.9%  1.4% body weight over 12
weeks, and PAR-1/ mice fed a control diet gained
15.5%  1.2% body weight. In addition, PAR-1/ mice
fed a Western diet gained 40.0%  3.4%* body weight
over 12 weeks, and PAR-1/ mice fed a Western diet
gained 34.8%  2.2%* body weight (*P  0.05 com-
pared with mice of the same genotype fed a control diet,
not significant between PAR-1/ and PAR-1/ mice
fed a Western diet). To determine whether PAR-1 con-
tributes to the development of steatosis in mice fed a
Western diet, we evaluated several markers of steatosis
in PAR-1/ and PAR-1/ mice fed a Western diet.
Microvesicular and macrovesicular steatosis occurred in
livers of PAR-1/ mice fed a Western diet. In contrast,
the severity of steatosis was greatly reduced in PAR-1/
mice fed a Western diet (Figure 3, B and C, E and F, H
and I, and K and L; also see Supplemental Table S1 at
http://ajp.amjpathol.org). In agreement with liver histo-
pathologic findings, hepatic triglyceride and cholesterol
levels increased in livers of PAR-1/ mice fed a Western
diet (Figure 4, A and B). The increase in liver triglyceride
accumulation was prevented by PAR-1 deficiency,
whereas cholesterol levels were not affected (Figure 4, A
and B). Serum triglyceride levels were slightly in-
creased in PAR-1/ mice fed a Western diet com-
pared with in PAR-1/ mice fed a control diet (Figure
4C), and serum cholesterol levels were increased in
PAR-1/ and PAR-1/ mice fed a Western diet (Fig-
ure 4D). However, there was no significant effect of




































































































Figure 4. Effect of PAR-1 deficiency on lipid accumulation in mice fed a
Western diet. PAR-1/ and PAR-1/ mice were fed either a control diet or
a Western diet for 12 weeks. Hepatic triglyceride (A), hepatic cholesterol (B),
serum triglyceride (C), and serum cholesterol (D) levels were determined.
Data are expressed as mean  SEM. n  7 to 10 mice per group. *P  0.05
versus mice of the same genotype fed a control diet; **P  0.05 versus
PAR-1/ mice fed the same diet.levels in mice fed a Western diet.Expression of mRNAs encoding the lipogenic genes
CD36, SCD1, SREBP-1c, and PPAR was increased in
livers of PAR-1/ mice fed a Western diet (Figure 5,
A–D). However, FAS mRNA expression was not
changed in mice fed a Western diet (Figure 5E). PAR-1
deficiency reduced the hepatic expression of CD36,
SCD1, and PPAR mRNAs but did not affect SREBP-1c
mRNA expression in mice fed a Western diet (Figure 5,
A–D). In addition, hepatic expression of CD36 and
SCD1 protein was increased in PAR-1/ mice fed a
Western diet (Figure 5F). In agreement with the reduc-
tion in CD36 mRNA in PAR-1/ mice fed a Western
diet, CD36 protein levels were reduced in PAR-1/
mice fed a Western diet (Figure 5F). In contrast to
expression of its mRNA, hepatic expression of SCD1
protein increased in PAR-1/ mice fed a Western diet
compared with in PAR-1/ mice fed a Western diet
(Figure 5F). PPAR protein expression in liver was not
affected by diet or genotype (data not shown). Taken
together, the data indicate that PAR-1 is essential for
steatosis in livers of mice fed a Western diet.
Hematopoietic Cell TF Deficiency Reduces
Inflammation in Livers of LDLr/ Mice Fed a
Western Diet
TF is the primary activator of the blood coagulation cas-
cade, and hematopoietic cells, such as monocytes,
could be a source of TF in obesity and MetS.42,43 Indeed,
TF expression by hematopoietic cells contributed to
thrombin generation in LDLr/ mice fed a Western
diet,43 a mouse model of hyperlipidemia and atheroscle-
rosis due to the inability to remove LDL cholesterol from
the circulation. These mice also develop fatty liver dis-
ease resembling NAFLD associated with MetS.19,47 To
specifically assess the role of TF on hematopoietic cells
in the development of steatosis and inflammation,
LDLr/ mice were irradiated, and the bone marrow was
repopulated with bone marrow from either heterozygous
(TF/) control mice or low-TF mice. Mice were then fed
a Western diet for 12 weeks. To analyze local coagulation
in the liver, we evaluated hepatic fibrin deposition. Fibrin
deposition was reduced in livers of LDLr/ mice with
low-TF bone marrow compared with in LDLr/ mice with
heterozygous (TF/) control bone marrow after 3
months on a Western diet (Figure 6, A and B). To deter-
mine the effect of hematopoietic cell TF deficiency on
hepatic inflammation, we evaluated hepatic cytokine ex-
pression and macrophage accumulation. Expression of
TNF and MCP-1 mRNAs was significantly reduced in
LDLr/ mice with low-TF bone marrow after being fed a
Western diet (Figure 7, A and B). Hepatic TNF and
MCP-1 protein levels also tended to decrease in LDLr/
mice with low-TF bone marrow after being fed a Western
diet, although this difference did not achieve statistical
significance (data not shown). Hepatic macrophage ac-
cumulation was also decreased in livers of LDLr/ mice
with low-TF bone marrow compared with LDLr/ mice
with TF/ control bone marrow (Figure 6, C and D). The
ity*mm
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utes to increased inflammation in livers of LDLr/ mice
fed a Western diet.
Hematopoietic Cell TF Deficiency Reduces
Steatosis in Livers of LDLr/ Mice Fed a
Western Diet
In agreement with previous studies examining NAFLD
development in LDLr/ mice,19,47,48 marked panacinar
microvesicular and macrovesicular steatosis occurred in
LDLr/ mice with TF/ bone marrow fed a Western diet
(Figure 6, E and G; also see Supplemental Table S1 at
http://ajp.amjpathol.org). The severity of steatosis was
markedly reduced in LDLr/ mice with low-TF bone
marrow fed a Western diet (Figure 6, F and H; also see
Supplemental Table S1 at http://ajp.amjpathol.org). Mir-
roring the effect of PAR-1 deficiency on hepatic steatosis,
liver triglyceride levels (Figure 8A), but not liver choles-
terol levels (Figure 8B), were reduced in LDLr/ mice
with low-TF bone marrow fed a Western diet compared
with in LDLr/ mice with TF/ bone marrow fed a
Western diet. Expression of mRNAs encoding the lipo-
genic genes CD36, SCD1, PPAR, and FAS, but not
SREBP-1c, was significantly reduced by hematopoietic
cell TF deficiency (Figure 9, A–E). Similar to PAR-1 defi-
















































































Figure 5. Effect of PAR-1 deficiency on lipogenic gene induction and protein
fed either a control diet or a Western diet for 12 weeks. Hepatic levels of CD
by real-time PCR. Data are expressed as mean  SEM of the fold change ver
and SCD1 protein levels were determined by Western blot analysis. Equal p
using Quantity One software and is expressed as mean  SEM and as intens
versus PAR-1/ mice fed the same diet.expression in livers of LDLr/ mice (Figure 9F). How-ever, hepatic SCD1 protein expression was increased in
livers of LDLr/ mice with low-TF bone marrow (Figure
9F), and hepatic PPAR protein expression was un-
changed between the two groups (data not shown). The
data indicate that hematopoietic cell–derived TF contrib-
utes to the development of steatosis in livers of LDLr/
mice fed a Western diet.
Discussion
A substantial increase in lipid accumulation occurs in
livers of patients with obesity and/or MetS49,50 and in
livers of mice fed a Western diet, contributing to the
development of NAFLD.18,47,51 Thrombin generation
is also increased in patients with obesity and/or
MetS,24,27,52,53 and systemic coagulation and hepatic
coagulation were increased in mice fed a Western diet
(Figure 1). The finding that PAR-1 deficiency and hema-
topoietic cell TF deficiency each reduced steatosis in
mice fed a Western diet strongly suggests a role for
thrombin signaling in the hepatic manifestation of MetS.
The studies presented herein demonstrate that increased
coagulation cascade activation may have a functional
consequence to promote an inflammatory environment
that leads to the development of steatosis, as both the
thrombin receptor PAR-1 and hematopoietic cell–derived




































sion in livers of mice fed a Western diet. PAR-1/ and PAR-1/ mice were
SCD1 (B), PPAR (C), SREBP-1c (D), and FAS (E) mRNA were determined
-1/ mice fed a control diet. n  7 to 10 mice per group. F: Hepatic CD36
ading was determined by Ponceau S staining. Densitometry was performed













steatosis in mice fed a Western diet.
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AJP November 2011, Vol. 179, No. 5Several studies have shown that inflammatory cells
and the mediators they produce are required for hepatic
steatosis in mice fed a Western diet. For example, deple-
tion of liver macrophages significantly reduced hepatic
steatosis in mice fed a Western diet.16,17 Moreover, inhi-
bition of the monocyte/macrophage chemokine MCP-
118,19 or TNF, a cytokine produced by Kupffer cells,46
significantly reduced hepatic steatosis. These studies












Figure 6. Effect of hematopoietic cell TF deficiency on coagulation, inflam-
mation, and steatosis in livers of LDLr/ mice fed a Western diet. LDLr/
mice with TF/ or low-TF bone marrow were fed a Western diet for 12
weeks. Representative photomicrographs showing fibrin staining (red) in
liver sections counterstained with DAPI (blue) (A and B), CD68 and F4/80–
stained (brown) liver sections (C and D), H&E-stained liver sections (E and
F), and Oil Red O–stained liver sections (G and H) in mice with TF/ (A, C,













































Figure 7. Effect of hematopoietic cell TF deficiency on hepatic inflammatory
cytokine induction in LDLr/ mice fed a Western diet. LDLr/ mice with
TF/ or low-TF bone marrow were fed a Western diet for 12 weeks. Hepatic
levels of TNF (A) and MCP-1 (B) mRNA were determined by real-time PCR.
Data are expressed as mean  SEM and as fold change versus LDLr/ mice
/with TF bone marrow. n  9 to 10 mice per group. *P  0.05 versus mice
with TF/ bone marrow.liver macrophages is essential for the development of
fatty liver disease in mice fed a Western diet. The present
results indicate that PAR-1 contributes to hepatic expres-
sion of MCP-1 and is required for liver macrophage ac-
cumulation in mice fed a Western diet. Initiation or ampli-
fication of the inflammatory response represents one
potential mechanism whereby thrombin activation of
PAR-1 could contribute to hepatic steatosis in mice fed a
Western diet (Figure 10).
Participation of the coagulation cascade in the inflam-
matory response accompanying hepatic steatosis seems
to be conserved in at least two models. In previous stud-
ies, we found that TF and PAR-1 contributed to MCP-1
mRNA and protein expression in mice fed an MCD diet.32
Hepatic macrophage accumulation was significantly re-
duced in PAR-1/ and low-TF mice fed an MCD diet.
However, in contrast to the Western diet model, neither
TF deficiency nor PAR-1 deficiency reduced hepatic ste-
atosis in mice fed an MCD diet.32 The rapid development
of severe hepatic steatosis in mice fed an MCD diet
represents a complex biochemical defect not resembling
the mechanism of steatosis in MetS.54 Unlike in mice fed
a Western diet, inflammatory cytokines, such as MCP-1
and TNF, do not contribute to hepatic steatosis in mice
fed an MCD diet.34,55 The fundamental contribution of
inflammatory cytokines to steatosis induced by either an
MCD diet or a Western diet could explain the striking
difference in the role of the coagulation cascade in he-
patic steatosis (Figure 10). Collectively, the present stud-
ies indicate that the coagulation cascade amplifies in-
flammatory cytokine expression in the MCD diet and
Western diet models but also contributes to hepatic ste-
atosis in the Western diet model, a more representative
model of NAFLD in humans.
A proper balance of fatty acid uptake, triglyceride syn-
thesis, and -oxidation is required to maintain lipid ho-
meostasis in the liver. Excess uptake or increased syn-
thesis of fatty acids provokes triglyceride synthesis and
storage by the liver, resulting in hepatic steatosis. Pro-
teins involved in lipid metabolism are regulated at multi-
ple levels, including gene expression, protein expres-
sion, and activation state, which all contribute to the
overall handling and metabolism of lipids during a dys-















































Figure 8. Effect of hematopoietic cell TF deficiency on hepatic lipid accu-
mulation in livers of LDLr/ mice fed a Western diet. LDLr/ mice with
TF/ or low-TF bone marrow were fed a Western diet for 12 weeks. Hepatic
triglyceride (A) and cholesterol (B) levels were determined. Data are ex-
pressed as mean  SEM. n  9 to 10 mice per group. *P  0.05 versus mice
with TF/ bone marrow.agulation cascade, through PAR-1 activation, contributes
express
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AJP November 2011, Vol. 179, No. 5to the regulation of genes involved in several facets of
lipid metabolism, including fatty acid uptake (CD36), tri-
glyceride synthesis (SCD1), and -oxidation (PPAR).
The decrease in PPAR mRNA levels is most likely a
consequence of reduced steatosis and was not accom-
panied by a change in hepatic protein expression. In
contrast to the expression of SCD1 mRNA, SCD1 protein
expression increased in PAR-1/ mice and in mice with
low-TF bone marrow fed a Western diet. Indeed, previous
studies have indicated that SCD1 is also regulated at the
posttranscriptional level.56 Mice lacking SCD1 in all cells
are protected from hepatic steatosis induced by a West-
ern diet, whereas liver-specific SCD1 deficiency does not
Figure 9. Effect of hematopoietic cell TF deficiency on hepatic lipogenic g
LDLr/ mice with TF/ or low-TF bone marrow were fed a Western diet
FAS (E) mRNA were determined by real-time PCR. Data are expressed as me
9 to 10 mice per group. F: Hepatic CD36 and SCD1 protein levels were dete
S staining. Densitometry was performed using Quantity One software and is
bone marrow.reduce hepatic steatosis in mice fed a Western diet.57
Taken together, these studies suggest that the effect of
either TF deficiency or PAR-1 deficiency on hepatic ste-
atosis is not a consequence of altered SCD1 expression.
Further studies evaluating the role of the coagulation
cascade in the dichotomous regulation of SCD1 mRNA
and protein expression are needed.
Expression of the fatty acid transporter CD36 in-
creased significantly in mice fed a Western diet, and the
increase in CD36 mRNA and protein was attenuated by
deficiency in PAR-1 or hematopoietic cell–derived TF.
Previous studies identified an association between he-
patic steatosis and CD36 expression in livers of patients
ction and protein expression in livers of LDLr/ mice fed a Western diet.
eeks. Hepatic levels of CD36 (A), SCD1 (B), PPAR (C), SREBP-1c (D), and
M and as fold change versus LDLr/ mice with TF/ bone marrow. n 
y Western blot analysis. Equal protein loading was determined by Ponceau
ed as mean  SEM and as intensity*mm2. *P  0.05 versus mice with TF/
Figure 10. Model-dependent difference in the
role of coagulation in hepatic steatosis. TF in-
creases thrombin generation, and thrombin ac-
tivation of PAR-1 increases inflammation, partic-
ularly MCP-1 expression. In mice fed a Western
diet, inflammatory mediators contribute to in-
creased steatosis in neighboring hepatocytes.
However, in mice fed an MCD diet, coagulation-
mediated increases in inflammatory mediators
do not contribute to increased steatosis. In ad-
dition, increased hepatic steatosis contributes to
further increases in inflammation in both models
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livers of mice fed a Western diet (Figures 5 and 9). More-
over, hepatic overexpression of CD36 caused hepatic
steatosis.59 Therefore, the coagulation cascade could
potentially contribute to hepatic steatosis by increasing
CD36 expression. One potential mechanism whereby
PAR-1 activation could contribute to CD36 expression is
indirectly via MCP-1 up-regulation because administra-
tion of an antagonist of the MCP-1 receptor CCR2 re-
duced CD36 expression in livers of obese mice.21 How-
ever, the mechanism whereby the coagulation cascade
regulates CD36 expression requires further investigation.
The present studies suggest that thrombin activation of
PAR-1 is vital to the development of hepatic steatosis in
mice fed a Western diet. PAR-1 expression was not de-
tected on rodent or human hepatocytes in previous stud-
ies,60,61 suggesting a requirement of PAR-1 expressed by
nonparenchymal cells in liver steatosis. Nonparenchymal
cells of the hepatic microcirculation, including Kupffer cells,
endothelial cells, and stellate cells, express PAR-1.61–63
Although the contribution of each nonparenchymal cell
population in the development of steatosis is not known,
several studies indicate that Kupffer cells contribute to ste-
atosis in rodent models by producing inflammatory media-
tors.16,17 MCP-1 is expressed by thrombin-stimulated
nonparenchymal cells,63 and MCP-1 stimulates lipid accu-
mulation in cultured hepatocytes.44 Taken together, the re-
sults indicate a complex mechanism of steatosis develop-
ment coordinated by the coagulation cascade by
stimulating the production of paracrine inflammatory medi-
ators by hepatic nonparenchymal cells that then cause lipid
accumulation in hepatocytes (Figure 10).
Identifying cell types that express TF in patients with
NAFLD could lead to a better understanding of the mech-
anisms whereby the coagulation cascade is activated in
MetS. One potential cellular source of TF in mice fed a
Western diet is the monocyte/macrophage. Indeed, TF
expression is increased on monocytes and/or Kupffer
cells in several rodent models of liver injury/disease and
in patients with liver disease, obesity, and MetS.42,64–69
We found that TF mRNA expression was increased in the
buffy coat (ie, white blood cells) from mice fed a Western
diet. In related studies, we found that hematopoietic cell
TF deficiency reduced plasma microparticle TF activity
and TAT levels in LDLr/ mice fed a Western diet.43
Moreover, hematopoietic cell TF deficiency reduced he-
patic fibrin deposition in mice fed a Western diet, sug-
gesting reduced thrombin generation in the liver. Al-
though the contribution of TF from other cellular sources
cannot be excluded, the finding that TF deficiency in
bone marrow–derived cells nearly prevented steatosis in
LDLr/ mice fed a Western diet suggests a critical role
for TF expressed by this cell population in hepatic ste-
atosis. The levels of several mediators that induce TF
expression in monocytes/macrophages, including endo-
toxin,64,69 proinflammatory cytokines,64 and oxidized
LDL,70 are increased in patients with obesity or MetS.
Moreover, several of these mediators have been impli-
cated in the development of liver steatosis.18,19,45,46 Ad-
ditional studies evaluating the mechanism whereby TFexpression increases on monocytes/macrophages in
MetS are needed.
In summary, the results of the studies presented herein
indicate that PAR-1 and hematopoietic cell TF are re-
quired for hepatic inflammation and steatosis in mice fed
a Western diet. These studies reveal an as yet uniden-
tified role of the coagulation cascade in promoting
Western diet–induced hepatic steatosis and highlight
the importance of circulating mediators in stimulating
lipid accumulation in parenchymal cells in NAFLD. The
contribution of the coagulation cascade to the devel-
opment of NAFLD as well as atherosclerosis and other
cardiac disorders may provide a connection between
multiple facets of MetS.
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